Lv75
4090 积分 2021-06-15 加入
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
8小时前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
11天前
已完结
Ⅰb类MET-TKI治疗MET异常非小细胞肺癌临床研究进展
25天前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
2个月前
已完结
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
3个月前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
3个月前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
3个月前
已完结
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support
4个月前
已完结
Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance
4个月前
已完结
皖公网安备34019202002308
